TrialBMC cancer2018

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

William P McGuire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.